<i>MDM4</i> amplification in atypical lipomatous tumors/well‐differentiated liposarcoma: Private event or alternative oncogenic mechanism?
Nadège Gruel(Inserm), Sarah Watson(Centre National de la Recherche Scientifique), Sylvie Jovelin(Institut Curie), Aurélien Maraval(Inserm), Khadija Aït Raïs(Institut Curie), Sylvie Bonvalot(Dana-Farber Cancer Institute), Nayla Nicolas(Institut Curie), Laetitia Fuhrmann(Institut Curie), Sophie El Zein(Institut Curie), Clément Bonnet(Université de Montpellier), Gaëlle Pierron(Institut Curie), Martial Caly(Université Paris Sciences et Lettres), Christelle Fieffe(Inserm), Dimitri Tzanis(Université Paris Cité)
Cited by 9
Related Papers
Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer
|Cancer Cell|2018|1.7k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
|Annals of Oncology|2021|978
Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|751
Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|641